WebTraductions en contexte de "rosuvastatin for the" en anglais-français avec Reverso Context : a combination comprising candesartan and rosuvastatin for the prevention or treatment of arteriosclerosis and for the prevention of cardiovascular events is described. WebMar 20, 2024 · Aspirin reduces the risk of major vascular events by 15% to 20% when used for primary CVD prevention 5. As a result, the role of aspirin in the prevention and …
Did you know?
WebAn open-label, three-treatment, fixed-sequence study was conducted. On Day 1, 20 mg of rosuvastatin was given to all subjects. After a 3-day washout period, the subjects received 20 mg of rosuvastatin plus 300 mg of epigallocatechin-3-gallate (EGCG), a major ingredient of green tea (Day 4). After a 10-day pretreatment of EGCG up to Day 14, they ... Webexamined the effects of rosuvastatin in primary prevention.20 Administration of rosuvastatin was associated with a signifi-cant decrease in the primary end point (a combination of myocardial infarction, stroke, arterial revascularization, hospi-talization for unstable angina, or death from CVD causes) by 44% compared to placebo (P < .00001).
WebOct 3, 2024 · The rising burden of cardiovascular diseases (CVDs) and projected mortality of about 4 million people by 2030 have posed a big public health threat. 1, 2 The Framingham Heart Study has demonstrated a direct relationship between the serum cholesterol levels and CVD such as coronary heart disease (CHD) and stroke. 3, 4 As per an estimate by the … WebConclusion The results of this study support the preferential prescription of moderate-intensity rosuvastatin over moderate-intensity atorvastatin for the secondary prevention of ischemic cardiovascular and cerebrovascular events in older patients aged ≥ 75 years.",
Web1 day ago · A planned interim analysis of data from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study found that participants who took pitavastatin calcium, a daily statin, lowered their risk of major adverse cardiovascular events by 35% compared with those receiving a placebo. Adverse drug events observed in the study … WebMar 29, 2024 · Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res 2024;120:229–43. 10.1161/CIRCRESAHA.116.308537; Kostapanos MS, Milionis HJ, Elisaf MS. An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther 2008;13:157–74. 10.1177/1074248408318628
WebDec 1, 2024 · Rosuvastatin has been shown to slow progression of atherosclerosis and to prevent cardiovascular disease, and is approved for those indications ... Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, …
WebMar 28, 2024 · Blaha MJ, Budoff MJ, DeFilippis AP, Blankstein R, Rivera JJ, Agatston A, O'Leary DH, Lima J, Blumenthal RS, Nasir K. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet. 2011 Aug 20;378(9792):684-92. doi: … lbt tws05whWebOct 1, 2024 · Current Literature. In patients age 75 and younger, the efficacy of statins for primary prevention is well-established on the basis of multiple randomized trials, which … lbt-tws05bkWebIn the secondary prevention of cardiovascular diseases, results showed that pravastatin and atorvastatin could reduce the incidence of major CVEs by 13% and 41%, respectively, compared with the control group, but there was no significant difference between other statins and control ( Table 2 ). In 10 head–head studies, 45 – 54 the influence ... lbt-tws05whWebNone of the dietary supplements demonstrated a significant decrease in LDL-C compared with placebo. Adverse event rates were similar across study ... Danielson E., Fonseca F.A., … lbt-tws05bk 評判WebA 2010 review concluded that treatment without history of cardiovascular disease reduces cardiovascular events in men but not women, and provides no mortality benefit in either sex. Two other meta-analyses published that year, one of which used data obtained exclusively from women, found no mortality benefit in primary prevention. lbt-tws05wh 口コミWebA NICE surveillance report which states that at the time the NICE guideline Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the … lbt-tws05 切れるWeb2. Major cardiovascular events (a composite of cardiovas-cular death, non-fatal MI or non-fatal stroke). We hypothesise that treatment with a statin (ator-vastatin 40 mg) will: (1) prolong overall disability-free survival, and (2) reduce the incidence of major cardio-vascular events among a primary prevention population aged ≥70 years. lbttws10bu